MIVI Neuroscience Welcomes Tim Hauch as Chief Financial Officer

EDEN PRAIRIE, Minn., July 8, 2021 (Newswire.com) - MIVI Neuroscience today announced that Tim Hauch has joined the Company as Chief Financial Officer. Tim most recently served as CFO with Respicardia from April 2010 through May 2021. During his tenure with Respicardia, he completed several successful private equity and debt offerings to finance Respicardia's product development, European and U.S. regulatory approvals and worldwide commercialization efforts. Respicardia was acquired by ZOLL Medical, an Asahi-Kasei company, in April 2021. Prior to joining Respicardia, Hauch was Vice President of Business Development with superDimension (acquired by Medtronic). Hauch also spent 17 years with Medtronic plc, holding multiple senior roles with responsibilities for identifying key growth markets and defining acquisition targets, as well as leading cross-functional teams through acquisition, investment, license, divestiture, and development transactions.

"We are delighted to welcome Tim to the MIVI team," said Bob Colloton, MIVI's Chief Executive Officer. "His breadth of experience and guidance will be invaluable as we continue to grow the organization and achieve our clinical and commercial goals."

"MIVI has a unique portfolio of innovative products in the rapidly growing stroke treatment market," said Hauch. "I could not be more pleased to join the Company at this exciting time and look forward to contributing to its success."

About MIVI Neuroscience
MIVI Neuroscience, Inc. is focused on developing and commercializing superior clinical solutions for neurointerventional procedures. Adoption of endovascular stroke therapy procedures is growing significantly worldwide since compelling data from multiple large-scale randomized trials in 2015 and 2016 confirmed the value to rapidly clear occlusive clots from large cerebral vessels. MIVI's innovative product portfolio provides physicians with unique devices designed to improve patient outcomes in these procedures by reducing complications, shortening procedure times and expanding treatment to more patients. More information about MIVI can be found on the website, www.mivineuro.com.

Source: MIVI Neuroscience